The trial included 33 subjects, with 24 randomized to andexanet alfa and nine to placebo. This first part of the Phase 3 ANNEXA-A trial achieved all of its primary and secondary endpoints with statistical significance (p value <0.0001). The full data set will be presented today in an oral presentation during the “Clinical Science: Special Reports” session at the American Heart Association (AHA) 2014 Scientific Sessions in Chicago, IL. Andexanet alfa produced rapid and nearly complete reversal (by approximately 94 percent, p value <0.0001) of the anticoagulant effect of Eliquis (apixaban) in healthy volunteers ages 50-75. (NYSE: PFE) today announced results from the first part of the Phase 3 ANNEXA™-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors – Apixaban) studies. Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |